August 10, 2022
Evaluating the antiviral efficacy of textiles against Monkeypox
Monkeypox has been hitting the headlines recently, as cases around the world increase – but what is it and how can you make label claims of efficacy against it?
Human Monkeypox (MPX) is a rare zoonotic disease caused by the Monkeypox virus (MPXV), and according to the NHS, the risk of catching it is low. However, it can be spread between people through any close physical contact with Monkeypox blisters or scabs, the coughs or sneezes of an infected person, and by touching contaminated materials, such as clothing, bedding, or towels.
Testing efficacy against the Monkeypox virus
The Monkeypox virus is an enveloped double-stranded DNA virus that belongs to the Orthopoxvirus genus of the Poxviridae family. As it is an enveloped virus, the antiviral efficacy of a product can be proven by testing against a surrogate virus. For brands and manufacturers wishing to make label claims of efficacy against Monkeypox, the Vaccinia virus can be used to substantiate such a claim.
Most disinfectants on the market already have the testing to support this claim (according to EN14476 and EN16777 standards), however, fabrics require specific testing to substantiate this.
Testing the antiviral activity of textiles against Monkeypox
Our experienced team can help determine the antiviral activity of your textile products by performing the ISO 18184 test. This standard provides a quantitative method to assess the antiviral performance of textile products, such as bedding, towels and other woven and knitted fabrics, fibres, yarns, and braids etc.
As well as the Vaccina virus (the surrogate virus for Monkeypox), this test is readily available for the Feline Coronavirus, Influenza H3N2, Influenza H1N1, and Feline Calicivirus. Other viruses may be available on request.